Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: A multicenter, randomized, phase III study
{{output}}
Background: SYSA1902 is a biosimilar of ustekinumab. Objective: Evaluate the efficacy and safety of SYSA1902 compared with reference ustekinuma... ...
